BAY 57-1293-d4 (Synonyms: Pritelivir-d4) |
| Catalog No.GC91407 |
BAY 57-1293-d4 est destiné à être utilisé comme étalon interne pour la quantification de BAY 57-1293 par GC ou LC-MS.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BAY 57-1293-d4 is intended for use as an internal standard for the quantification of BAY 57-1293 by GC- or LC-MS. BAY 57-1293 is an orally bioavailable helicase-primase inhibitor.1 It inhibits the ATPase activity of herpes simplex virus (HSV) helicase-primase (IC50 = 30 nM). It inhibits HSV replication in Vero cells (IC50 = 20 nM for both HSV-1 and HSV-2) and is also active against porcine and bovine HSV strains (IC50s = 5 and 0.12 μM, respectively). In vivo, oral administration of BAY 57-1293 is effective against HSV-1 and HSV-2 in a lethal challenge model (ED50 = 0.5 mg/kg in mice and rats) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats.1,2 It is also effective in a guinea pig model of genital herpes and a mouse model of ocular herpes. BAY 57-1293 reduces levels of amyloid-beta (Aβ) and phosphorylated Tau in HSV-1 infected Vero cells.3
Review for BAY 57-1293-d4
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for BAY 57-1293-d4
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *